Metal-Dependent Regulation of ATP7A and ATP7B in Fibroblast Cultures by Malgorzata Lenartowicz et al.
fnmol-09-00068 August 17, 2016 Time: 17:39 # 1
ORIGINAL RESEARCH
published: 18 August 2016
doi: 10.3389/fnmol.2016.00068
Edited by:
Gaiti Hasan,
National Centre for Biological
Sciences, UK
Reviewed by:
Beena Pillai,
Council of Scientific and Industrial
Research (CSIR), India
Sonal Srikanth,
University of California, Los Angeles,
USA
*Correspondence:
Lisbeth B. Møller
lisbeth.birk.moeller@regionh.dk
Received: 10 May 2016
Accepted: 26 July 2016
Published: 18 August 2016
Citation:
Lenartowicz M, Moos T, Ogórek M,
Jensen TG and Møller LB (2016)
Metal-Dependent Regulation
of ATP7A and ATP7B in Fibroblast
Cultures. Front. Mol. Neurosci. 9:68.
doi: 10.3389/fnmol.2016.00068
Metal-Dependent Regulation of
ATP7A and ATP7B in Fibroblast
Cultures
Malgorzata Lenartowicz1, Torben Moos2, Mateusz Ogórek1, Thomas G. Jensen3 and
Lisbeth B. Møller4,5*
1 Department of Genetics and Evolution, Institute of Zoology, Jagiellonian University, Krakow, Poland, 2 Section of
Neurobiology, Biomedicine, Institute of Medicine and Health Technology, Aalborg University, Aalborg, Denmark, 3 Department
of Biomedicine, Aarhus University, Aarhus, Denmark, 4 Applied Human Molecular Genetics, Kennedy Center, Department of
Clinical Genetics, Copenhagen University Hospital – Rigshospitalet, Glostrup, Denmark, 5 Department of Science, Systems
and Models, Roskilde University, Roskilde, Denmark
Deficiency of one of the copper transporters ATP7A and ATP7B leads to the rare
X-linked disorder Menkes Disease (MD) or the rare autosomal disorder Wilson disease
(WD), respectively. In order to investigate whether the ATP7A and the ATP7B genes
may be transcriptionally regulated, we measured the expression level of the two genes
at various concentrations of iron, copper, and insulin. Treating fibroblasts from controls
or from individuals with MD or WD for 3 and 10 days with iron chelators revealed that
iron deficiency led to increased transcript levels of both ATP7A and ATP7B. Copper
deficiency obtained by treatment with the copper chelator led to a downregulation of
ATP7A in the control fibroblasts, but surprisingly not in the WD fibroblasts. In contrast,
the addition of copper led to an increased expression of ATP7A, but a decreased
expression of ATP7B. Thus, whereas similar regulation patterns for the two genes
were observed in response to iron deficiency, different responses were observed after
changes in the access to copper. Mosaic fibroblast cultures from female carriers of
MD treated with copper or copper chelator for 6–8 weeks led to clonal selection. Cells
that express the normal ATP7A allele had a selective growth advantage at high copper
concentrations, whereas more surprisingly, cells that express the mutant ATP7A allele
had a selective growth advantage at low copper concentrations. Thus, although the
transcription of ATP7A is regulated by copper, clonal growth selection in mosaic cell
cultures is affected by the level of copper. Female carriers of MD are rarely affected
probably due to a skewed inactivation of the X-chromosome bearing the ATP7A
mutation.
Keywords: copper, menkes disease, wilson disease, regulation, iron–copper interaction
INTRODUCTION
ATP7A and ATB7B are copper ATPases of the P-type 1B family. Mutations in the genes that encode
these copper transporters are responsible for Menkes disease (MD) and Wilson disease (WD),
respectively. MD is a severe X-linked copper deficiency disorder which typically leads to death
before the age of 3 years. The copper deficiency is caused by a defective ATP7A-mediated transport
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of copper from the intestine into the portal circulation. As a
consequence, the clinical features of MD are a malfunction of a
large number of copper-requiring enzymes. WD is an autosomal
copper toxicity disorder. Typically, copper accumulates in the
liver as a result of a disrupted ATP7B-driven copper export from
the hepatocytes. Both transporters are responsible for copper
export, but in different cell types. The ATP7A is expressed in
almost all cell types and tissues, but its expression levels differ
among the cells and tissues and are age-dependent (Lenartowicz
et al., 2010). In contrast, ATP7B is predominantly expressed in the
adult liver Lenartowicz et al., 2015).
Fibroblasts from MD patients accumulate large amounts of
copper as a result of impaired copper extrusion in contrast
to fibroblasts from WD patients, in which no accumulation of
copper is observed (own unpublished results). Both ATP7A and
ATP7B are expressed in fibroblasts, but the expression level of
ATP7A is approximately 10 times higher than that ofATP7B (own
unpublished results).
Female carriers are mosaics of wild-type and mutant cells
due to random X-inactivation, and are rarely affected. A likely
explanation is that the majority (more than 90%) of the females
have a skewed inactivation of the X-chromosome bearing the
ATP7A mutation and therefore, predominantly express the
normal allele (Møller et al., 2012). However, from a large number
of fibroblast cultures we were able to identify cultures from three
MD carriers, including one manifesting carrier with MD, with an
even or almost even X-inactivation pattern (Møller et al., 2012).
Not much is known about the possible transcriptional
regulation of ATP7A and ATP7B. It seems that regulation and
copper homeostasis occur predominantly in post-translational
mechanisms (van den Berghe and Klomp, 2010). This study was
designed to test the transcriptional effect on ATP7A and ATP7B
in fibroblast cultures after short (3 days) or longer (10 days)
term treatment with iron and copper and chelators thereof,
and insulin. Short-term treatment might exhibit a rapid effect
on transcriptional levels, whereas long-time treatment may also
involve cellular selection. We treated fibroblasts obtained from
controls with both intact ATP7A and intact ATP7B, fibroblasts
from MD with only intact ATP7B, and fibroblasts from WD with
only intact ATP7A.
Furthermore, we looked at clonal growth selection as an
effect of functional ATP7A gene expression, and the cellular
concentration of copper. Mosaic cultures obtained from female
MD carriers with an even X-inactivation pattern, were treated
with copper or the copper chelator (Bathocuproine disulphonate,
BCS).
RESULTS
Transcriptional Expression of ATP7A and
ATP7B in Fibroblast Cultures
To test for a possible transcriptional regulation of ATP7A
and ATP7B, we treated fibroblasts from patients with MD
or WD and control fibroblasts with various chemicals and
hormones: BCS (copper chelator, Bathocuproinedisulfonic
acid disodium salt), DEDTC (copper chelator, Sodium
diethyldithiocarbamate trihydrate), CuCl2, Ferrozine (Fe2+
chelator) DTPA (Diethylenetriaminepentaacetic acid, Fe2+
chelator) and insulin. The cells were treated for 3 days and
10 days before RNA was harvested and analyzed using RT-PCR.
The expression levels of ATP7A and ATP7B were calculated and
normalized to the expression level of the housekeeping genes
GAPDH (Table 1).
Treatment with iron chelator (Ferrozine, DTPA) led to an
increased expression of both ATP7A and ATP7B. Treatment
with FeCl3 led to an increased expression of ATP7B in the
control fibroblasts, but only after 10 days. Treatment with
insulin led to an increased expression of ATP7A, whereas no
effect was observed for ATP7B. The effect was transient (only
observed after 3 days) and was only significant in control
cells. Furthermore, treatment with CuCl2 led to an increased
expression of ATP7A, but a decreased expression of ATP7B.
The effect on ATP7A was only transient in control cells (3 days
only), whereas it was stable in WD cells (3 and 10 days). This
indicates that in WD cells with no functional ATP7B gene,
an increased expression of ATP7A is of significant importance
in the presence of copper overload. In contrast, a decreased
expression of ATP7B was only observed after 10 days of CuCl2
treatment. Interestingly, treatment with copper chelator (BCS)
led to a decreased expression of ATP7A, but only in control
cells and only after 10 days of treatment. No decrease of
ATP7A was observed in WD cells. BCS had no effect on
ATP7B.
ATP7A transcripts could not be detected in MD fibroblasts,
because the ATP7A gene in these cells was almost completely
deleted (ex2–ex23) There was some expression of ATP7B
in WD fibroblasts, but since the mutation [c.2333G > T,
p.(Arg778Leu)] might affect splicing and/or RNA stability
its expression was relatively low. Interestingly, however,
the expression level of ATP7A increased after long-term
culture in the control medium, whereas the expression level
of ATP7B was more stable except in the WD fibroblasts,
where a significant increase was observed. Importantly,
the expression of ATP7B was constantly high in MD
fibroblasts.
Since ATP7A expression was increased in a high copper
environment and decreased in a low copper environment, we
tested the impact of ATP7A on cell survival as an effect of
copper concentration. In order to perform this test, clonal growth
selection was investigated in mosaic cultures from heterozygous
females.
Copper-Dependent Clonal Selection in
Mosaic Cultures
Fibroblasts from MD carriers with even X-inactivation patterns
are mosaic with respect to functional ATP7A due to the
inactivation of one of the two X chromosomes in each cell.
A fraction of the cells express only mutated ATP7A transcript and
behave like cells from an MD patient with an increased copper
uptake, whereas other cells express normal ATP7A transcript and
behave like control cells. Such cultures are suited for determining
the effects of functional versus mutated ATP7A, since the cells
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potentially only differ with respect to genes expressed from the
two X-chromosomes.
The cells were maintained in normal medium (control
conditions), medium with CuCl2, or medium with BCS for
several weeks, respectively, before DNA was harvested and the
X-inactivation pattern determined. The methylation status of
the androgen receptor (AR) gene was used as an indicator for
X-chromosome inactivation. DNA from the index male was
included in the X-inactivation test to identify the pattern of AR
on the mutated allele.
Skewed inactivation of cells that express the mutant
X-chromosome was observed after cultivation in the
presence of 400 µM CuCl2 (ratio 100:0 in carrier 1 and
82:18 in carrier 2), indicating a selection of cells with
the X-chromosome harboring the normal ATP7A gene
active. In contrast, selection for cells with the mutant
X-chromosome active was observed after incubation with
10 µM BCS (ratio 0:100 in carrier 2 and 39:61 in carrier 1).
No significant effects were observed in the normal control cells
(Figure 1A).
To challenge the system further we repeated the experiment,
but cultivated the heterozygous fibroblasts (carrier 1 and
carrier 3) for 8 weeks instead of 6 weeks in the presence
of either BCS (10 or 50 µM as indicated) or CuCl2 (100
and 200 µM). After 8 weeks, the cells’ ability to grow was
almost exhausted. In the presence of BCS, almost all cells
in the population had the mutant X chromosome active,
whereas in the presence of CuCl2, the entire cell population
had the normal X-chromosome active. After 8 weeks,
skewed increased X-inactivation of the X-chromosome
harboring the mutated ATP7A allele was also observed
in the cells grown in normal medium (Figure 1B). An
illustration of the experiment and its outcome is shown in
Figure 2.
The Expression of ATP7A Transcript in
Copper- and BCS-Treated Mosaic
Cultures
The treated 8-week-old cultures from carrier 3 were further used
to investigate whether the X-inactivation pattern, hence reflecting
the expression of mutant versus normal ATP7A transcripts
using RT-PCR analysis (Figure 3). Carrier 3 is heterozygous
for the mutation IVS8+5G > A. This mutation leads to 100%
skipping of exon 8 in the index male (Figure 3, lane I). The
amount of expressed wild-type versus mutant transcript can
therefore easily be visualized after RT-PCR. Analyzing RNA
from the mosaic cell culture grown in normal medium as
well as in copper-supplemented medium, resulted in a PCR
product identical to the wild-type transcript, whereas the major
transcript obtained from cells grown in the presence of BCS
corresponded to a mutant transcript: a transcript without
exon 8, identical to the transcript observed in the index male
patient (Figure 3, lane I). However, a faint band corresponding
to the wild-type transcript was also observed. These results
indicate that the expression of ATP7A follows the X-inactivation
pattern.
DISCUSSION
Both P-type ATPases (ATP7A and ATP7B), are involved
in copper eﬄux and intracellular sequestration. The overall
topologies and structures of ATP7A and ATP7B are similar
and they are approximately 60% homologous. They have eight
transmembrane domains with six copper-binding motifs in
the cytoplasmic N-terminal region. The N-terminal metal-
binding domains interact with ATOX1 and receive copper in
the form of Cu+. The transmembrane hydrophobic domains
(TMDs) anchor the protein in the membrane and form a
channel for the ATP-dependent transport of copper ions across
the plasma or intracellular membranes. Cellular ATP7A and
ATP7B play a dual role depending on the copper status.
Under normal physiological conditions they are TGN-resident
proteins and mediate copper loading of copper-dependent
enzymes in the secretory pathway. When the intracellular copper
concentration is elevated, ATP7A and ATP7B – after their
re-localization/re-distribution to the plasma membrane or to
vesicles – are essential for copper eﬄux or secretion. ATP7A
and ATP7B contain similar catalytic domains and functional
motifs that govern their intracellular cycling between the TGN
and the plasma membrane (La Fontaine and Mercer, 2007;
Lutsenko et al., 2007; Gupta and Lutsenko, 2009; Barry et al.,
2010).
However, whereas both ATP7A and ATP7B preserve
cellular copper homeostasis by expelling copper ions from
the cell’s interior to prevent toxic accumulation, there are
some differences. When the cells are exposed to a rise in
copper concentrations, ATP7A is translocated to the basolateral
membrane in polarized cells, whereas ATP7B is transported
to the apical membrane (Mercer et al., 2003; La Fontaine
and Mercer, 2007; Gupta and Lutsenko, 2009; Veldhuis et al.,
2009; Barry et al., 2010). Furthermore, whereas ATP7A in the
secretory pathway, delivers copper to lysyl oxidase, tyrosinase,
dopamine-β-hydroxylase, and peptidylglycine-α-amidating
monooxygenase among others (Petris et al., 2000; Hardman
et al., 2007a; Lutsenko et al., 2007), the ATP7B protein
participates in copper-loading of apo-ceruloplasmin (Barry et al.,
2010).
We found both similarities and differences in the
transcriptional regulation of ATP7A and ATP7B. A summary
is shown in Table 2. We found that treatment with insulin led
to a transient increase in ATP7A transcript, but had no effect
on ATP7B transcript in control fibroblasts. This observation
is in agreement with previous observations by Hardman et al.
(2007b) who reported that treating Jeg-3 cells with insulin for
72 h (3 days) leads to an increase in the ATP7A transcript but
has no effect on the ATP7B transcript. Insulin (and ostrogen)
also changed the localization of ATP7A in the Jeg-3 cells;
ATP7A was more diffusely distributed in the cytoplasm with
increased accumulation at the basolateral membrane relative to
the untreated cells (Hardman et al., 2007a). Our results indicate
that the effect of transcriptional regulation of the ATP7A gene by
insulin is not restricted to the placental cells and is closely related
to the control of copper transport from mother to fetus, but it is
also observed in other cell types.
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FIGURE 1 | X-inactivation patterns before and after 6 or 8 weeks of treatment with CuCl2 or BCS. Fibroblasts were obtained from female carriers of ATP7A
mutations or from females with no mutations in the ATP7A gene (control samples). The X-inactivation patterns were measured before and after 6 (A) or 8 (B) weeks
of culture using normal medium or normal medium with different concentrations of BCS or CuCl2 as indicated in the figure. Each column shows the inactivation
percentage of the two X-chromosomes (gray and black bars, respectively). In the carriers, the black bar represents inactivation of the X-chromosomes with ATP7A
mutations, whereas the gray bar represents inactivation of the X-chromosomes without ATP7A mutations. Control 1 (3540-86H); Control 2: (M95-24668H); Control
3: (M85-2427H); Carrier 1: (3373-84H, heterozygote for the ATP7A mutation p.Gly1315Arg); Carrier 2: (3372-84H, heterozygote for the ATP7A mutation
p.Gly1315Arg); Carrier 3: (M85-3426H (F1), heterozygote for the ATP7A mutation c.1946+5G > A).
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FIGURE 2 | Illustration of the outcome after copper or BCS treatment of mosaic fibroblast cultures for 6–8 weeks.
Iron deficiency led to an increased expression of both ATP7A
and ATP7B, but copper-deficiency only led to a decreased
expression of ATP7A. The addition of copper led to an increased
expression of ATP7A, but a decreased expression of ATP7B.
The changes in transcripts (increase or decrease) were less
than twofold. We have previously shown that the relative
transcriptional level of ATP7A in control fibroblasts vary by
almost a factor 2 (Paulsen et al., 2006) making it unlikely that
the observed transcriptional regulation has any physiological
significance.
Interactions between iron and copper metabolism were
documented over a century ago, but the homeostatic effects
at the molecular level and the involvement of ATP7A and
ATP7B in this regulation have not been fully elucidated.
Interaction between iron and copper is essential for metal
homeostasis because, e.g., copper-dependent ferroxidases like
ceruloplasmin, hephaestin, and zyclopen facilitate dietary iron
absorption by oxidizing ferrous Fe++ to ferric Fe+++ iron
(Vulpe et al., 1999; Collins et al., 2010; Gambling et al., 2011;
Vashchenko and MacGillivray, 2013). Any impairment to the
incorporation process of copper results in the secretion of an
apo-ceruloplasmin that lacks any ferroxidase activity, and is
rapidly degraded in the plasma (Hellman and Gitlin, 2002;
Kono, 2013). Atp7b −/− mice, which constitute an animal
model of WD, display disturbances in iron metabolism related
to low serum ceruloplasmin oxidase activity (Merle et al.,
2010). Furthermore, a complex interplay between these two
metals seems to involve multiple copper-dependent regulatory
mechanisms that act in concert to control the expression of
ferroportin, the only identified ferrous iron transporter that
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FIGURE 3 | Selection of the two different fibroblast cell types from
carrier 3, heterozygous for the mutation c.1946+5G > A. The fibroblasts
were BCS and/or copper treated for 8 weeks. A cDNA fragment from exon 6
to exon 10 spanning the mutation was amplified by PCR with the primer-pair
5′-gccactgtgatagaaaatgctgat-3/′5′-caatagttgcttctgtagcttgtagtg-3′. I: cDNA
from a male index with the mutation c.1946+5G > A, expressed only a
mutant transcript in which exon 8 is missing. C: cDNA from heterozygous
fibroblasts cultured in normal medium that predominantly expressed the
wild-type transcript. BCS: cDNA from heterozygous fibroblasts, cultured in the
presence of BCS, predominantly expressed a product in which exon 8 is
missing. CuCl2 (I) and CuCl2(II): cDNA from heterozygous fibroblasts cultured
in the presence of 100 µM CuCl2 (I) or 200 µm CuCl2 (II), predominantly
expressed the wild-type product with exon 8. The PCR products were
separated on a 2% agarose gel and visualized with ethidium bromide.
exports iron from cells to plasma (Xie and Collins, 2011;
Starzyn´ski et al., 2013).
An increased expression of ATP7A has previously been
identified in intestinal epithelial cells of iron-deficient rats and
confirmed by in vivo and in vitro analyses (Collins et al., 2005,
2009; Collins, 2006). During iron deficiency many tissues become
hypoxic. Cellular responses to hypoxia are mainly regulated by
the activation of transcription factors called hypoxia-inducible
factors (HIFs) (Hashimoto and Shibasaki, 2015). Iron deficiency
in the intestinal epithelial cells leads to the upregulation of the
ATP7A gene and iron-homeostasis related genes: the cell surface
ferrireductase gene Dtcyb, the iron ion transporter gene DMT1
and the basolateral iron exporter ferroportin gene (FPN) (Xie
and Collins, 2011, Xie and Collins, 2013). Results of previous
studies indicate that HIF2α binds to the promotor region of
the ATP7A gene, the analysis of which revealed that this region
contains three phylogenetically conserved, putative hypoxia-
response elements (HRE; 5′-NCGTGN-3′) (Xie and Collins,
2011, 2013).
Fibroblasts incubated for 3–10 days and mosaic cultures
incubated for 6–8 weeks revealed that a large amount of
functional ATP7A is advantagous in high concentrations of
copper, whereas a low amount/zero of functional ATP7A is
advantageous in low concentrations of copper. Both after 3
and 10 days of treatment, the effect on the transcription level
could be visualized, whereas in the mosaic cell culture the
effect was seen on clonal selection. The lack of decreased
expression of ATP7A in WD fibroblasts after BCS treatment
might be a result of the absence of functional ATP7B
protein in these cells, thereby reducing the demand for a
downregulation of ATP7A. Furthermore, in both types of
experiments we found that cultures grown in basic, control
medium also led to an increased expression of ATP7A and
increased the growth of cells with the wild-type ATP7A.
An increase in the ATP7B transcript level after long-term
culturing was only observed for the WD fibroblasts. This
might indicate that even under normal conditions, an increased
amount of ATP7A is an advantage, whereas an increased
amount of ATP7B is an advantage only if the level of
functional ATP7B is lower than normal, e.g., as a result of
mutations.
A large fraction of the cells died in a mosaic culture with
cells from a female carrier grown in medium supplemented
with 100–400 µM CuCl2 or 10–50 µM BCS, respectively, for
either 6 or 8 weeks. This suggests that growth selection is
a likely explanation for the observed skewed X-inactivation
pattern in these cells. Our results indicate that the two different
cell types have complementary growth characteristics. In the
presence of a low concentration of copper, the selection
went against cells with the active normal X-chromosome,
whereas in the presence of a high concentration of copper,
the selection went against cells with the active mutant
X-chromosome.
Amplification of the ATP7A gene has previously been
observed in selected CHO cells after stepwise increments
of copper in the growth medium (Camakaris et al., 1995).
The copper concentration was increased from 142 µM to
205 µM over 27 days, and the cells were cultured for an
additional 99 days at the latter concentration. Both mechanisms:
ATP7A gene amplification, and growth advantage of the cells
that express the normal ATP7A gene show that the ATP7A
gene is essential for the cells under conditions with high
concentrations of copper. In contrast, the growth advantage
of the cells that express the mutant ATP7A gene indicates
that the absence of a functional ATP7A gene is more
advantageous if no copper is present. To our knowledge,
a positive selection of cells without a functional ATP7A
gene an effect of the lack of copper has not been reported
previously.
Affected carriers of MD are rare. In a total of 517 families
we know of 9 confirmed affected females. However, we are
aware of the fact that there are mildly affected females
who have not been characterized as manifesting carriers. We
know of several girls with pili torti, hypopigmentation of
the skin or other mild symptoms of MD. The total number
of females with symptoms is unknown. It is possible that
copper treatment during pregnancy decreases the brain damage
in heterozygous female fetuses both indirectly by clonal cell
selection of the developing cells that express the normal ATP7A
gene, and directly by the transport of copper to copper-
requiring enzymes. Thus the serum copper level in pregnant
heterozygous females should remain within the upper level
of the reference interval in order to diminish the symptoms
of MD and, in particular, brain damage in both hemi- and
heterozygous fetuses. Copper supplements during pregnancy
should be considered.
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TABLE 2 | Summary of ATP7A and ATP7B transcriptional regulation in fibroblast cultures.
ATP7A (control cells) ATP7A (WD cells) ATP7B (control cells) ATP7B (WD cells) ATP7B (MD cells)
+ insulin ↑ No effect No effect No effect No effect
− Fe ↑ ↑ ↑ ↑ ↑
+ Fe No effect No effect ↑ No effect No effect
− Cu ↓ No effect No effect No effect No effect
+ Cu ↑ ↑ ↓ ↓ No effect
The X-inactivation pattern in a MD mice model should
be determined. It would reveal the effect of prenatal copper
treatment on the X-inactivation pattern in brain tissue in
heterozygous female mouse fetuses.
In X-linked recessive diseases, females are rarely affected,
probably due to skewed inactivation of the X-chromosome
harboring the mutant allele. Identification of small molecules
leading to negative selection against cells deficient in
the disease-related gene might be relevant for other
X-linked diseases where the phenotype in females could be
hampered due to selection of cells with the active normal
X-chromosome.
MATERIALS AND METHODS
Chemicals
BCS (Bathocuproinedisulfonic acid disodium salt, Cu+
chelator), DEDTC (Sodium diethyldithiocarbamate trihydrate,
copper chelator), CuCl2, Ferrozine (Fe2+ chelator) DTPA
(Diethylenetriaminepentaacetic acid, Fe2+ chelator). BCS
was from Pierce1, all other chemicals, including insulin were
from Sigma2. The cells were grown in normal medium
(see below) supplemented with: BCS (150 µM), CuCl2
(150 µM), DEDTC (50 µM), Ferrozine (5 mM), DTPA
(10 µM), FeCl3 (150 µM), Insulin (20 ng/ml), 20 ng/ml
Insulin + 150 µM BCS, or 20 ng/ml Insulin + 150 µM
CuCl2.
Cell Cultures
Skin fibroblasts obtained from the patients and
controls were cultured in a 1:1 mixture of RPMI 16403
(ICN Biomedicals, Inc) with 20 mM HEPES and a
nutrient mixture of F-10 Ham’s medium, supplemented
with 7.5% Amnio Max – C100 supplement4 (Life
Technologies), 4% fetal calf serum, penicillin, and
streptomycin.
Control fibroblast culture, a culture from a MD patient
(with a deletion of exon 3–23 of ATP7A (c.121-?-8333+?del)
and a culture from a WD patient homozygous for the
ATP7B mutation c.2333G >T, p.(Arg778Leu) was used
for the 3–10 day-treatment experiments. The mutations
1http://www.piercechemical.com
2https://www.sigmaaldrich.com/denmark.html
3http://www.mpbio.com
4http://www.lifetech.com
were verified in DNA isolated from blood from the
patients.
Two cultures were obtained from unaffected carriers,
Carrier 1 (family 9720,3373-84H) and Carrier 2 (family
9720; 3372-84H) and used for 6–8 week-treatment
experiments, Carrier 1 and Carrier 2 are both heterozygote
for the ATP7A mutation p.Gly1315Arg). One culture was
obtained from a manifesting carrier, Carrier 3 (family
F1, M85-3426H) heterozygote for the ATP7A mutation
c.1946+5G > A. In addition three control cultures were
included:
Control 1 (family 9720, 3540-86H), Control 2 (family
F1, M95-24668H), and Control 3 (family F4, M85-2427H).
The families have been described previously (Møller et al.,
2012).
The fibroblast cultures were cultured at 37oC as described
previously (Møller et al., 2012). The cells were treated for
3 days, 10 days, 6 or 8 weeks with either BCS or CuCl2 and
subsequently harvested for RNA or DNA isolation. The RNA
was used for RT-PCR analysis and the DNA for X-inactivation
studies.
Quantitation of ATP7A and ATP7B
Transcript
Total RNA was isolated with the Rneasy Mini kit (Qiagen) and
single-stranded cDNA was synthesized by reverse transcription
using the High-Capacity cDNA Archive Kit (applied Biosystems).
For relative quantification of ATP7A and ATP7B transcripts Real-
time PCR was carried out on cDNA with an ABI7300 Genetic
Analyzer in accordance with the manufacturer’s instructions
(Applied Biosystems, Foster, CA, USA). We used FAM-labeled
Taq-Man probes and primers that anneal to the junction
between exon 11/exon 12 in ATP7A, and a FAM-labeled
Taq_Man probe annealing to the junction between exon
13/exon 14 in ATP7B, respectively, (Applied Biosystems assay
numbers: Hs00921956_m1 and Hs01075297_m1). A FAM-
probe and primers to human GAPDH were used (Applied
Biosystems assay numbers: 4326317E) as an endogenous
control.
X-Inactivation Pattern
DNA was isolated by standard procedures (Grimberg et al.,
1989). The methylation status of the AR gene was used
as an indicator for X-chromosome inactivation (La Spada
et al., 1991; Allen et al., 1992). The amplified products
were analyzed in an ABI 3130XL Genetic Analyzer, and the
ratio between the signal intensities of the two alleles was
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calculated using GeneMapper 3.0 software (Applied Biosystems,
Foster, CA, USA). The ratio between signals from the two
alleles in the undigested sample was used as a correction
factor.
Statistical Methods
Data are presented as mean values ± SD. Statistical analysis was
performed with the bilateral Student’s t-test using Statgraphics
5.1 (Manugistics, USA). P ≤ 0.05, P ≤ 0.01, and P ≤ 0.001 were
considered significant and are denoted with one, two and three
asterisks, respectively.
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